GLMD

Galmed Pharmaceuticals Ltd.

0.36 USD
+0.02 (+4.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Galmed Pharmaceuticals Ltd. stock is down -12.2% since 30 days ago. The next earnings date is Jun 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 72.73% of the previous 10 June’s closed higher than May.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine.